UY38673A - Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista - Google Patents

Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista

Info

Publication number
UY38673A
UY38673A UY0001038673A UY38673A UY38673A UY 38673 A UY38673 A UY 38673A UY 0001038673 A UY0001038673 A UY 0001038673A UY 38673 A UY38673 A UY 38673A UY 38673 A UY38673 A UY 38673A
Authority
UY
Uruguay
Prior art keywords
biodegradable polymer
poly
segments
gnrh
agonist
Prior art date
Application number
UY0001038673A
Other languages
English (en)
Inventor
Avinash Nangia
Arthur Mclane John
Original Assignee
Tolmar Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Int Ltd filed Critical Tolmar Int Ltd
Publication of UY38673A publication Critical patent/UY38673A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Cleaning Or Drying Semiconductors (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Se proporciona una formulación de liberación prolongada para su uso en un método para el tratamiento de la pubertad precoz central (CPP) en pacientes pediátricos de 2 años de edad o mayores. La formulación de liberación prolongada comprende leuprolida o una sal farmacéuticamente aceptable de esta, un polímero biodegradable y un solvente orgánico biocompatible. El polímero biodegradable está compuesto de segmentos de copolímero de poli(láctido-co-glicólido) (PLG), segmentos de copolímero de poli(ácido láctico-co-ácido glicólico) (PLGA), segmentos de polímero de poli(láctido) (PL), segmentos de polímero de poli(ácido láctico) (PLA), o una combinación de estos.
UY0001038673A 2019-04-22 2020-04-22 Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista UY38673A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837094P 2019-04-22 2019-04-22
US16/451,625 US20200330547A1 (en) 2019-04-22 2019-06-25 Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition

Publications (1)

Publication Number Publication Date
UY38673A true UY38673A (es) 2020-11-30

Family

ID=72833377

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038673A UY38673A (es) 2019-04-22 2020-04-22 Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista

Country Status (15)

Country Link
US (2) US20200330547A1 (es)
EP (1) EP3958837A1 (es)
JP (1) JP7438239B2 (es)
KR (1) KR20220027058A (es)
CN (1) CN113993536A (es)
AR (1) AR118753A1 (es)
AU (1) AU2020262383B2 (es)
BR (1) BR112021021127A2 (es)
CA (1) CA3137505A1 (es)
EA (1) EA202192878A1 (es)
IL (1) IL287434A (es)
MX (1) MX2021012815A (es)
SG (1) SG11202111638TA (es)
UY (1) UY38673A (es)
WO (1) WO2020217170A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023007367A (es) 2020-12-23 2023-09-07 Tolmar International Ltd Metodos y sistemas para conjuntos de valvulas de jeringa mezcladoras.
US20220331395A1 (en) * 2021-04-07 2022-10-20 Proneurogen, Inc. Extended-release injectable gel formulations containing angiotensin-(1-7) oligopeptides or variants thereof
EP4319790A1 (en) * 2021-04-08 2024-02-14 Enteris BioPharma, Inc. Methods of treatment of pediatric puberty using oral formulations of leuprolide
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US8062652B2 (en) * 2004-06-17 2011-11-22 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating precocious puberty
US10285936B2 (en) * 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
JP2022529807A (ja) 2022-06-24
US20220313772A1 (en) 2022-10-06
WO2020217170A1 (en) 2020-10-29
KR20220027058A (ko) 2022-03-07
JP7438239B2 (ja) 2024-02-26
MX2021012815A (es) 2022-06-08
US20200330547A1 (en) 2020-10-22
EP3958837A1 (en) 2022-03-02
CA3137505A1 (en) 2020-10-29
AU2020262383B2 (en) 2023-06-22
AU2020262383A1 (en) 2021-11-25
IL287434A (en) 2021-12-01
CN113993536A (zh) 2022-01-28
AR118753A1 (es) 2021-10-27
EA202192878A1 (ru) 2022-03-28
BR112021021127A2 (pt) 2021-12-28
SG11202111638TA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
UY38673A (es) Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista
CY1122771T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων
Gardner et al. Biomaterials‐based modulation of the immune system
AR107985A2 (es) Formas farmacéuticas resistentes a la rotura con liberación sostenida
CR7654A (es) Una combinacion de azelatina y esteroides
US20200253661A1 (en) Devices and methods for enhanced denervation procedures
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
US20140274881A1 (en) Biodegradable therapeutic nanoparticles containing an antimicrobial agent
US20100015237A1 (en) NSAID Delivery from Polyarylates
US11446392B2 (en) Biomimetic vesicles and uses thereof
CY1105515T1 (el) Μεθοδος παρασκευης στερεων διασπορων
NZ592998A (en) Depot formulation comprising oxtreotide and two linear polylactide-co-glycolide polymers (PLGAs)
Parent et al. One-week in vivo sustained release of a peptide formulated into in situ forming implants
Singhal et al. Fractional laser ablation for the cutaneous delivery of triamcinolone acetonide from cryomilled polymeric microparticles: creating intraepidermal drug depots
BRPI0418294A (pt) composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
BR112015011294A2 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco de uso humano pentoxifilina
JP2018527397A5 (es)
AR034044A1 (es) Composicion para el tratamiento reconstituyente en enfermedades de cartilago
AR106085A1 (es) Formulaciones de olanzapina de liberación sostenida
BRPI0923161B1 (pt) dispositivo implantável de uma peça contendo rilpivirina
US20170258716A1 (en) Anti-cancer agent for use in combination therapy of high intensity focused ultrasound therapy and anti-cancer agent therapy
Laulicht et al. Are in vivo gastric bioadhesive forces accurately reflected by in vitro experiments?
Lesnak et al. Selective androgen receptor modulator microparticle formulation reverses muscle hyperalgesia in a mouse model of widespread muscle pain
EP3134118B1 (en) Particulate vaccine formulations for inducing innate and adaptive immunity
Kong et al. Enhanced bioavailability by orally administered sirolimus Nanocrystals